Last reviewed · How we verify

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (ATPase)

NCT05014464 PHASE2 RECRUITING

This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.

Details

Lead sponsorHunan Province Tumor Hospital
PhasePHASE2
StatusRECRUITING
Enrolment90
Start dateSat Nov 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionSun Aug 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

China